Prof. Gopal C. Kundu, Director R&D, KIIT-DU, Awarded Prestigious J.C. Bose National Fellowship : Ommtv Round The Clock
Prof. Gopal C. Kundu, Director R&D, KIIT-DU, Awarded Prestigious J.C. Bose National Fellowship : Ommtv Round The Clock
BIDYADHAR BARIK MADHU
Prof. Gopal C. Kundu, Director R&D, KIIT-DU, Awarded Prestigious J.C. Bose National Fellowship : Ommtv Round The Clock
KIIT Deemed to be University congratulates Prof. Gopal C. Kundu, Director R&D, KIIT-DU, Professor of Biotechnology, KIIT School of Biotechnology and Professor of Medicine and Molecular Research, Kalinga Institute of Medical Sciences, for being awarded the J. C. Bose National Fellowship for four years (2023-2027). The J.C. Bose fellowship is awarded to active scientists in recognition for their outstanding performance in research at the National and International levels. This fellowship is scientist-specific and very selective.
The Fellowship has been awarded to Prof. Kundu in recognition of his exceptional research in cancer biology, cancer stem cells, tumor immune microenvironment, nanomedicine, drug development and cancer therapy. He has made significant and innovative contributions in understanding tumor-biology, cancer stem cells, tumor-stroma interaction, angiogenesis, cancer therapeutics, biomarker development and nanomedicine. Prof. Kundu has published 128 papers in leading national and international journals and holds one US and three Indian patents. His total citations are 10,273, h-index of 58 and i-10 index of 105.
He has been elected as a Fellow of Indian National Science Academy (INSA). He is also Fellow of National Academy of Sciences, India (NASI), Indian Academy of Sciences (IAS), Royal Society of Chemistry (FRSC) and International Association of Advanced Materials (FIAAM), Sweden. He has received several national and international awards.
Prof. Kundu is determined to take research at KIIT to global recognition. His future research plans are to establish breast, prostate, skin, gall bladder and head and neck oral cancer specific Patient Derived Xenograft (PDX) models, primary cultures and cell lines from patients and PDX models and identify potential therapeutic targets and therapeutically relevant biomarkers from cell lines, PDX and patients’ specimens using genomics and proteomics approaches for the effective targeting of cancer cells and screening of new drugs, repurposing of drugs using PDX models.
He is grateful to the Founder of KIIT & KISS, Prof. Achyuta Samanta, and the Vice Chancellor of KIIT-DU, Prof. Saranjit Singh for their continuous support towards research and development at KIIT University.
